You are here

larotrectinib

Shattering an old record, FDA quickly OKs pioneering, site-agnostic cancer drug larotrectinib from Loxo and Bayer

Shattering an old record, FDA quickly OKs pioneering, site-agnostic cancer drug larotrectinib from Loxo and Bayer

Endpoints

personalized medicine

Flag link:

Loxo's targeted therapy holds up to Roche challenge

Loxo's targeted therapy holds up to Roche challenge

Biopharma Dive

Flag link:

3 Biotechs Awaiting FDA Approval Decisions

3 Biotechs Awaiting FDA Approval Decisions

Motley Fool

Flag link:

FDA starts speedy review of Loxo’s site-agnostic cancer drug larotrectinib

FDA starts speedy review of Loxo’s site-agnostic cancer drug larotrectinib

Fierce Biotech

metastatic solid tumors

Flag link:

[video]Is Loxo Oncology's Deal With Bayer Bad News?

[video]Is Loxo Oncology's Deal With Bayer Bad News?

Motley Fool

Flag link:

Loxo Oncology's Up 230% in the Past Year -- Can You Still Make Money Buying It?

Loxo Oncology's Up 230% in the Past Year -- Can You Still Make Money Buying It?

Motley Fool

Flag link:

Loxo Oncology Shares Rally, Despite Diluting Investors

Loxo Oncology Shares Rally, Despite Diluting Investors

Motley Fool

Flag link:

A New Cancer Drug Helped Almost Everyone Who Took It. Almost. Here's What It Teaches Us

A New Cancer Drug Helped Almost Everyone Who Took It. Almost. Here's What It Teaches Us

Forbes

clinical trials

Flag link:

Loxo takes center stage at ASCO with its groundbreaking shot at a biomarker-based cancer drug approval

Loxo takes center stage at ASCO with its groundbreaking shot at a biomarker-based cancer drug approval

Endpoints

Flag link: